Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0UL2X
|
|||
Drug Name |
CC-90010
|
|||
Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
Company |
CelgeneSummit, NJ
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [1] |
KEGG Pathway | SNARE interactions in vesicular transport | |||
Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.